Yonsei University study links rapid diabetes progression to pancreatic cancer risk

A study led by researchers at Yonsei University Severance Hospital has found that the initial severity and rapid progression of newly diagnosed type 2 diabetes are significant indicators of pancreatic cancer risk. The research, published in the journal ‘Gut’, analyzed data from over 400,000 individuals tracked for up to 15 years using National Health Insurance Service records.

The findings indicate that patients requiring more intensive initial treatment face higher risks. Compared to non-diabetic controls, those requiring no medication had a 3.01-fold increased risk, oral hypoglycemic agents users had a 4.32-fold risk, and those requiring insulin had a 5.6-fold risk. The risk was even more pronounced for pancreatic cancer diagnosed within three years of diabetes onset.

Crucially, the speed of disease progression serves as a major warning sign. Patients who required a transition from oral medication to insulin within six months of their initial diagnosis showed a 26.54-fold increase in pancreatic cancer risk compared to non-diabetic individuals.

While the absolute risk of pancreatic cancer in new diabetes patients remains low (under 1–2%), researchers suggest that monitoring the intensity of diabetes treatment and the speed of clinical worsening could be vital for early detection strategies.